Biolase (BIOLQ) 10-Q2012 Q1 Quarterly report

Filed: 10 May 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: accelerated, Accelerating, assistance, CAO, CEO, Chairman, collaboration, commitment, core, DaVinci, Delta, Deltalaser, derecognized, Dermalase, Division, doubled, Easy, energy, Epic, Federico, Flavorflow, fourth, freight, Geyserlaser, Geyser™are, Group, inability, injunctive, iStar, iStarlaser, leading, maintain, maximize, MDX, newly, Oculase, pending, Pignatelli, promote, Proprietary, relief, retrospective, review, salary, SeeNote, selected, Solution, source, supplier, twelve, Utah

Removed: accept, Administration, agent, agree, alleged, allocate, allocated, announced, applied, apply, arrange, arranged, Ascendiant, assessment, assured, audit, began, behalf, binding, borrowed, building, case, chart, collectability, Comfort, commercially, competition, concurrent, consideration, Controlled, counterparty, covenant, credited, dated, decision, decline, declining, deficit, delay, deliverable, delivered, delivery, depreciated, determinable, discussing, doubtful, dropped, Drug, duly, Europe, evaluate, evidence, evidenced, exhausted, Exhibit, expand, fee, field, file, finite, fixed, Food, Forbearance, fraud, frederick, furry, German, Germany, hierarchy, historically, improved, inception, informed, installation, institutional, iPlus™are, issue, iv, Jet, knowledge, land, lesser, letter, licensing, long, maker, met, mutually, NASDAQ, nature, negotiated, noted, objective, October, offered, offering, onForm, open, ordered, Overview, ownership, party, permitted, persuasive, plaintiff, Power™and, preferred, privately, professional, prospectively, qualified, ratably, Registrant, registration, reimburse, relationship, remained, removed, rendered, Renshaw, repayment, requested, resulting, resume, Rodman, Rule, sale, satisfy, selling, SensaTouch, separate, shelf, shipment, shipped, significantly, step, sufficiency, suit, sum, supplement, Supply, thereunto, title, trade, trademark, trading, transferred, treated, typically, unavailable, undelivered, undersigned, unfair, usable, utilization, violation, VSOE, waived, warrant, written, Zap

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

BIOLQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BIOLASE Technology, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Frederick D. Furry, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(i) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 10, 2012		/s/ FREDERICK D. FURRY
		Frederick D. Furry
		Chief Financial Officer (Principal Financial and Accounting Officer)